Thrombosomes® in Bleeding Thrombocytopenic Patients Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

January 7, 2022

Study Completion Date

January 7, 2022

Conditions
ThrombocytopeniaHematologic MalignancyBone Marrow AplasiaMyeloproliferative DisordersMyelodysplastic SyndromesPlatelet Refractoriness
Interventions
BIOLOGICAL

Thrombosomes

Human platelet derived lyophilized hemostatic

BIOLOGICAL

Liquid Stored Platelets (LSP)

Leukocyte reduced apheresis platelets or whole blood derived pooled platelet concentrate equivalent (4-6 units)

Trial Locations (6)

20007

Medstar Georgetown, Washington D.C.

37232

Vanderbilt University Medical Center, Nashville

77030

MD Anderson Cancer Center, Houston

91010

City of Hope, Duarte

Unknown

Rambam Medical Center, Haifa

Helse Bergen Haukeland University Hospital, Bergen

Sponsors
All Listed Sponsors
lead

Cellphire Therapeutics, Inc.

INDUSTRY

collaborator

Department of Health and Human Services

FED